Abstract | OBJECTIVES: Daily injections of anakinra, an interleukin-1-receptor antagonist, have been reported to control effectively the symptoms and signs of Schnitzler syndrome, a rare acquired autoinflammatory disorder, presenting in adulthood by intermittent fever, urticarial rash, and paraproteinemia, usually IgM. Canakinumab, a fully human interleukin-1β monoclonal antibody, approved for the cryoporin-associated periodic syndrome, may offer a practical advantage because its half-life of ∼28 days may allow less frequent dosing. The present trial was designed to test canakinumab in patients with Schnitzler syndrome. METHODS: A patient with Schnitzler syndrome was treated with canakinumab, 150 mg subcutaneously injection every 8 weeks for 6 consecutive months. Injections were resumed in case of a flare following discontinuation. RESULTS: CONCLUSIONS:
|
Authors | Steven Vanderschueren, Daniël Knockaert |
Journal | Seminars in arthritis and rheumatism
(Semin Arthritis Rheum)
Vol. 42
Issue 4
Pg. 413-6
(Feb 2013)
ISSN: 1532-866X [Electronic] United States |
PMID | 22901459
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | Copyright © 2013 Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Interleukin-1beta
- canakinumab
|
Topics |
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Humans
- Interleukin-1beta
(antagonists & inhibitors)
- Male
- Remission Induction
- Schnitzler Syndrome
(drug therapy)
- Treatment Outcome
|